1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4.
Voice of Customer
5.
Impact of COVID-19
on Global Thalassemia Treatment Market
6.
Clinical Trial
Analysis
6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Breakdown of Pipeline, By Development Phase
6.5. Breakdown of Pipeline, By Status
6.6. Breakdown of Pipeline, By Study Type
6.7. Breakdown of Pipeline, By Region
6.8. Clinical Trials Heat Map
7.
Global Thalassemia
Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1. By Type
(Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow
Transplant, Others)
7.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
7.2.2. By
Region
7.2.3. By
Company (2022)
7.3. Market Map
7.3.1.
By Type
7.3.2.
By Region
8.
North America
Thalassemia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Type (Blood Transfusions, Iron
Chelation Therapy, Blood & Bone Marrow Transplant, Others)
8.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
8.2.2.
By Country
8.3. North America: Country Analysis
8.3.1.
United States
Thalassemia Treatment Market Outlook
8.3.1.1.
Market Size &
Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share &
Forecast
8.3.1.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
8.3.1.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
8.3.2.
Canada Thalassemia
Treatment Market Outlook
8.3.2.1.
Market Size &
Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share &
Forecast
8.3.2.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy, Blood
& Bone Marrow Transplant, Others)
8.3.2.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
8.3.3.
Mexico Thalassemia
Treatment Market Outlook
8.3.3.1.
Market Size &
Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share &
Forecast
8.3.3.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
8.3.3.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.
Europe Thalassemia
Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.2.2.
By Country
9.3. Europe: Country Analysis
9.3.1.
Germany Thalassemia
Treatment Market Outlook
9.3.1.1.
Market Size &
Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share &
Forecast
9.3.1.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.3.1.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.3.2.
France Thalassemia
Treatment Market Outlook
9.3.2.1.
Market Size &
Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share &
Forecast
9.3.2.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.3.2.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.3.3.
United Kingdom
Thalassemia Treatment Market Outlook
9.3.3.1.
Market Size &
Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share &
Forecast
9.3.3.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.3.3.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.3.4.
Spain Thalassemia
Treatment Market Outlook
9.3.4.1.
Market Size &
Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share &
Forecast
9.3.4.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.3.4.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
9.3.5.
Italy Thalassemia Treatment
Market Outlook
9.3.5.1.
Market Size &
Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share &
Forecast
9.3.5.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
9.3.5.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.
Asia-Pacific
Thalassemia Treatment Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.2.2. By Country
10.3.
Asia-Pacific:
Country Analysis
10.3.1. China Thalassemia Treatment
Market Outlook
10.3.1.1.
Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share &
Forecast
10.3.1.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.3.1.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.3.2. Malaysia Thalassemia Treatment
Market Outlook
10.3.2.1.
Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share &
Forecast
10.3.2.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.3.2.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.3.3. Thailand Thalassemia Treatment
Market Outlook
10.3.3.1.
Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share &
Forecast
10.3.3.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.3.3.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.3.4. Vietnam Thalassemia Treatment
Market Outlook
10.3.4.1.
Market Size &
Forecast
10.3.4.1.1.
By Value
10.3.4.2.
Market Share &
Forecast
10.3.4.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.3.4.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
10.3.5. India Thalassemia Treatment
Market Outlook
10.3.5.1.
Market Size &
Forecast
10.3.5.1.1.
By Value
10.3.5.2.
Market Share &
Forecast
10.3.5.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
10.3.5.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
11.
South America
Thalassemia Treatment Market Outlook
11.1.
Market Size &
Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
11.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
11.2.2. By Country
11.3.
South America:
Country Analysis
11.3.1. Brazil Thalassemia Treatment
Market Outlook
11.3.1.1.
Market Size &
Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share &
Forecast
11.3.1.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
11.3.1.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
11.3.2. Argentina Thalassemia Treatment
Market Outlook
11.3.2.1.
Market Size &
Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share &
Forecast
11.3.2.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
11.3.2.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
11.3.2. Colombia Thalassemia Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
11.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
12.
Middle East and
Africa Thalassemia Treatment Market Outlook
12.1.
Market Size &
Forecast
12.1.1. By Value
12.2.
Market Share &
Forecast
12.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.2.2. By Country
12.3.
MEA: Country
Analysis
12.3.1. Egypt Thalassemia Treatment Market Outlook
12.3.1.1.
Market Size &
Forecast
12.3.1.1.1.
By Value
12.3.1.2.
Market Share &
Forecast
12.3.1.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.1.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.2. South Africa Thalassemia Treatment
Market Outlook
12.3.2.1.
Market Size &
Forecast
12.3.2.1.1.
By Value
12.3.2.2.
Market Share &
Forecast
12.3.2.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.2.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.3. Saudi Arabia Thalassemia Treatment
Market Outlook
12.3.3.1.
Market Size &
Forecast
12.3.3.1.1.
By Value
12.3.3.2.
Market Share &
Forecast
12.3.3.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.3.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.4. UAE Thalassemia Treatment Market Outlook
12.3.4.1.
Market Size &
Forecast
12.3.4.1.1.
By Value
12.3.4.2.
Market Share &
Forecast
12.3.4.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.4.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.5. Bahrain Thalassemia Treatment
Market Outlook
12.3.5.1.
Market Size & Forecast
12.3.5.1.1.
By Value
12.3.5.2.
Market Share &
Forecast
12.3.5.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.5.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.6. Qatar Thalassemia Treatment
Market Outlook
12.3.6.1.
Market Size &
Forecast
12.3.6.1.1.
By Value
12.3.6.2.
Market Share &
Forecast
12.3.6.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.6.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.7. Kuwait Thalassemia Treatment
Market Outlook
12.3.7.1.
Market Size &
Forecast
12.3.7.1.1.
By Value
12.3.7.2.
Market Share &
Forecast
12.3.7.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.7.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
12.3.8. Turkey Thalassemia Treatment
Market Outlook
12.3.8.1.
Market Size &
Forecast
12.3.8.1.1.
By Value
12.3.8.2.
Market Share &
Forecast
12.3.8.2.1.
By Type (Blood Transfusions, Iron Chelation Therapy,
Blood & Bone Marrow Transplant, Others)
12.3.8.2.1.1.
By Iron Chelation Therapy (Exjade/Jadenu (deferasirox),
Ferriprox (deferiprone), Desferal (deferoxamine))
13. Market Dynamics
13.1.
Drivers
13.2.
Challenges
14. Market Trends & Developments
14.1.
Product Launches
14.2.
Mergers &
Acquisitions
14.3.
Recent Developments
15. Global Thalassemia Treatment Market: SWOT
Analysis
16. Porter’s Five Forces Analysis
16.1.
Competition in the
Industry
16.2.
Potential of New
Entrants
16.3.
Power of Suppliers
16.4.
Power of Customers
16.5.
Threat of Substitute
Products
17. Competitive Landscape
17.1.
Business Overview
17.2.
Company Snapshot
17.3.
Products &
Services
17.4.
Financials (In case
of listed companies)
17.5.
Recent Developments
17.6.
SWOT Analysis
17.6.1.
Bluebird bio, Inc.
17.6.2. Acceleron Pharma, Inc.
17.6.3. Celgene Corporation
17.6.4. GlaxoSmithKline plc
17.6.5. Incyte Corporation
17.6.6. La Jolla Pharmaceutical Company
17.6.7. Ionis Pharmaceuticals, Inc.
17.6.8. Sanofi S.A.
17.6.9. Lonza Group Ltd.
17.6.10.
ApoPharma Inc
18.
Strategic Recommendations
19. About Us & Disclaimer